UNSPSC 51362507: Amperozide hydrochloride

This classification denotes a serotonin antagonist with the molecular formula C23H29F2N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8V2171U69N, chemically known as 4-(4,4-bis(p-fluorophenyl)butyl)-n-ethyl-1-piperazinecarboxamide but more generally known as amperozide hydrochloride, which bears US NIH Compound Identifier 73333. Most nations, for tariff and trade purposes, schedule amperozide hydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, AMPEROZIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Amperozide hydrochloride bears US NLM identifiers UMLS ID C0957053 and NCI Concept Code C77259. SMILES: CCNC(=O)N1CCN(CC1)CCCC(C2CCC(CC2)F)C3CCC(CC3)F.CL.

UNSPSC 51362507 Amperozide hydrochloride is a Commodity code that in practice captures a narrow slice of state and local pharmaceutical procurement — specifically the acquisition of individual drug products and related health intervention systems by public health authorities and state pharmacy benefit programs. Recent opportunities tagged to this code show state and local governments buying naloxone delivery systems, generic multi-source pharmaceuticals distributed through authorized wholesalers, and exploring direct-to-manufacturer prescription supply models to manage pharmacy costs and improve fulfillment efficiency. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances administered by state procurement offices (Minnesota Department of Administration). The scope spans both acute intervention products such as naloxone kits for emergency response and the broader infrastructure of generic pharmaceutical supply chain management for state employee health plans and Medicaid-equivalent programs.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capability information on direct-to-manufacturer prescription programs for the state's pharmacy benefit initiative. The Minnesota Department of Administration's Office of State Procurement, administering the Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, serving multiple state and local government facilities across Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC). Vendors must demonstrate cGMP and DSCSA compliance, maintain wholesaler relationships with chargeback capability, and accept a 3 percent administrative fee; the MMCAP contract runs two years with optional extensions.